United States-based Halodine LLC has collaborated with Emery Pharma, a boutique contract research and development company, it was reported on Thursday.
The collaboration is aimed at advancing the development of Halodine's proprietary antiseptic platform for COVID-19.
The partnership will see Emery Pharma's use its experience in antimicrobial and antiviral screening and drug development, while Halodine is to use its expertise in topical antiviral drug development.
Emery Pharma says that it will leverage its microbiology, virology, and bioanalytical experience to aid in developing this novel product, as well as other drugs to help treat COVID-19.
More Than 13% of Northwell Health Care Providers Test Positive for Antibodies
CTI BioPharma reports six months ended 30 June 2020 financial results
PreveCeutical to begin clinical trials of cannabinoid Sol-Gel under the COVID-19 programme
Celularity awarded USD750,000 CIRM grant to advance COVID-19 treatment in California
Johnson & Johnson to supply 100m doses of investigational COVID-19 vaccine to the US Government
IMV Receives Canadian Government Funding for COVID-19 Vaccine Phase 1 Clinical Study